Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models

Cancer Research

Volumn 62, Issue 6, 2002, Pages 1724-1729

  Friedlos, Frank ^a   Davies, Lawrence ^a   Scanlon, Ian ^a   Ogilvie, Lesley M ^a   Martin, Janet ^a   Stribbling, Stephen M ^a   Spooner, Robert A ^a   Niculescu Duvaz, Ion ^a   Marais, Richard ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 FLUORO 4 [BIS(2 CHLORETHYL)AMINO]BENZOYLGLUTAMIC ACID; 3,5 DIFLUORO 4 [BIS(2 IODOETHYL)AMINO]BENZOYLGLUTAMIC ACID; 4 [BIS(2 IODOETHYL)AMINO]PHENYLOXYCARBONYLGLUTAMIC ACID; BETA GALACTOSIDASE; CARBOXYPEPTIDASE G2; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BYSTANDER EFFECT; CELL DIFFERENTIATION; CELL KILLING; CELL SURFACE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-GALACTOSIDASE; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; GLUTAMIC ACID; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PRODRUGS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037086075     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Prodrugs in cancer chemotherapy
2. Bioreducible mustards - A paradigm for hypoxiaselective prodrugs of diffusible cytotoxins (HPDCS)
3. Novel anthracycline prodrugs
4. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)
5. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations
6. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer
7. Catalytic antibodies as magic bullets
8. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study
9. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a Phase I clinical trial
10. Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma
11. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques
12. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives
13. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for Cancer
14. Cancer gene therapy: Developments to 2000
15. Prodrug activation enzymes in cancer gene therapy
16. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767P) for antibody-directed enzyme prodrug therapy (ADEPT)
17. Self-immolative anthracycline prodrugs for suicide gene therapy
18. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors
19. Production of first generation adenovirus vectors: A review
20. Non-viral vectors in cancer gene therapy: Principles and progress
21. Tumor-targeted Salmonella as a novel anticancer vector
22. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model
23. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector
24. Systemic p53 gene therapy in combination with radiation results in human tumor regression
25. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy
26. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy
27. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug
28. Gene directed enzyme prodrug therapy (GDEPT) with a mustard prodrug/carboxypeptidase G2 combination
29. Self-immolative nitrogen mustard prodrugs for suicide gene therapy
30. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia
31. Biodistribution of an antibody-enzyme conjugate for ADEPT in nude mice bearing a human colon adenocarcinoma xenograft
32. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect